Stock ICCC IMMUCELL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials ImmuCell Corporation

Equities

ICCC

US4525253062

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
5.14 USD +0.78% Intraday chart for ImmuCell Corporation +2.39% +0.98%
Apr. 09 Immucell Corporation Reports Unaudited Sales Results for the Three Months and Twelve Months Ended March 31, 2024 CI
Apr. 02 ImmuCell Shares Fall After $20 Million Mixed Securities Shelf Filing MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 38.65 37.13 42.92 61.94 47.26 39.45
Enterprise Value (EV) 1 45.89 36.84 45.7 62.02 53.94 55.16
P/E ratio -16.7 x -27.1 x -42 x -776 x -18.9 x -6.79 x
Yield - - - - - -
Capitalization / Revenue 3.52 x 2.71 x 2.8 x 3.22 x 2.55 x 2.26 x
EV / Revenue 4.18 x 2.68 x 2.98 x 3.22 x 2.91 x 3.16 x
EV / EBITDA -73.3 x 28 x 47.3 x 22.8 x 286 x -22 x
EV / FCF -18.4 x -210 x -21.2 x -37.9 x -11.7 x -12.2 x
FCF Yield -5.43% -0.48% -4.72% -2.64% -8.54% -8.17%
Price to Book 1.8 x 1.28 x 1.52 x 1.9 x 1.56 x 1.58 x
Nbr of stocks (in thousands) 5,485 7,210 7,213 7,742 7,747 7,751
Reference price 2 7.046 5.150 5.950 8.000 6.100 5.090
Announcement Date 3/22/19 3/27/20 3/30/21 3/30/22 3/29/23 4/1/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 10.99 13.72 15.34 19.24 18.57 17.47
EBITDA 1 -0.6259 1.314 0.9669 2.719 0.1886 -2.504
EBIT 1 -2.147 -0.9539 -1.38 0.2574 -2.299 -5.221
Operating Margin -19.54% -6.95% -9% 1.34% -12.38% -29.88%
Earnings before Tax (EBT) 1 -1.86 -1.267 -1.032 -0.0691 -2.486 -5.77
Net income 1 -2.322 -1.296 -1.022 -0.0783 -2.494 -5.775
Net margin -21.13% -9.44% -6.66% -0.41% -13.43% -33.05%
EPS 2 -0.4232 -0.1900 -0.1417 -0.0103 -0.3220 -0.7500
Free Cash Flow 1 -2.492 -0.1753 -2.156 -1.636 -4.606 -4.509
FCF margin -22.68% -1.28% -14.05% -8.5% -24.8% -25.81%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/22/19 3/27/20 3/30/21 3/30/22 3/29/23 4/1/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 7.24 - 2.79 0.09 6.69 15.7
Net Cash position 1 - 0.29 - - - -
Leverage (Debt/EBITDA) -11.58 x - 2.882 x 0.0327 x 35.45 x -6.275 x
Free Cash Flow 1 -2.49 -0.18 -2.16 -1.64 -4.61 -4.51
ROE (net income / shareholders' equity) -10.2% -5.11% -3.57% -0.26% -7.92% -20.9%
ROA (Net income/ Total Assets) -4% -1.67% -2.18% 0.38% -3.22% -7.36%
Assets 1 58 77.61 46.82 -20.64 77.52 78.46
Book Value Per Share 2 3.900 4.020 3.920 4.210 3.920 3.220
Cash Flow per Share 2 0.4500 0.8700 0.9600 1.320 0.7500 0.1300
Capex 1 2.03 1.39 4.07 2.61 3.98 1.89
Capex / Sales 18.48% 10.14% 26.54% 13.56% 21.41% 10.83%
Announcement Date 3/22/19 3/27/20 3/30/21 3/30/22 3/29/23 4/1/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IMMUCELL CORPORATION Stock ImmuCell Corporation
+0.98% 39.84M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ICCC Stock
  4. Financials ImmuCell Corporation